Abstract: A silicon oxide layer is formed on the back surface of an N-type silicon wafer; an N-type silicon layer is formed on the silicon oxide layer, wherein the phosphine concentration of the N-type silicon layer is within a first preset concentration range; and an antireflection layer is formed on the N-type silicon layer and a back electrode is formed on the antireflection layer. In the high-temperature annealing process, hydrogen atoms can be bound by phosphine, such that membrane explosion caused by the escape of hydrogen atoms is avoided, an open-circuit voltage, the conversion efficiency and a filling factor can be improved, a back passivation effect can be enhanced, and the quality of a cell piece can be improved.

Abstract: A frequency selective surface unit includes dielectric substrate(s), first resonant pattern(s) and second resonant pattern(s). A first resonant pattern is disposed on a dielectric substrate. Each of the first resonant pattern(s) includes a plurality of protruding portions. A second resonant pattern is disposed on the dielectric substrate; and the second resonant pattern and the first resonant pattern have a distance therebetween in a direction parallel to a plane where the dielectric substrate is located and/or a direction perpendicular to the dielectric substrate.

Abstract: An antenna is provided. The antenna includes a microstrip feed line, a ground plate, a slot extending through the ground plate, and a radiating plate. The radiating plate is on a side of the ground plate and the slot away from the microstrip feed line. The radiating plate is configured to receive a signal from the microstrip feed line by aperture coupling through the slot. The radiating plate includes a plurality of radiating blocks spaced apart from each other.

Abstract: An antenna and an electronic device are provided in the present disclosure. The antenna includes a first conductive layer, a dielectric layer, and a second conductive layer which are stacked; the first conductive layer is provided as a microstrip line structure; the second conductive layer is provided with a radiation structure and a director; the radiation structure includes a first edge and a second edge disposed oppositely along a first direction; the radiation structure is provided with a first slot, a second slot, and a third slot that are sequentially communicated along the first direction and away from the first edge, the first slot is circular, the second slot is rectangular, and the third slot gradually increases in dimension in the second direction; the director is disposed on the second conductive layer and located at a side of the third slot away from the second slot.

Abstract: This application discloses a battery tray and a battery formation and capacity-grading device. The battery tray includes a fixed frame; and a fixed component located in the fixed frame, the fixed component including a first limiting assembly and a second limiting assembly, the first limiting assembly including at least two first limiting members which extend along a first direction respectively and are spaced apart along a second direction which intersects the first direction, the second limiting assembly being connected to the first limiting assembly and including at least two second limiting members which are disposed along the first direction and are connected with the first limiting members to form a limiting space for accommodating a battery cell, and the second limiting members being movably disposed along the first limiting members in the first direction.

Abstract: An acoustic device comprises a shell and a sound producing assembly, the shell being provided with an installation hole and a sound outlet, and the sound producing assembly being fixed inside the shell. The sound producing assembly has a diaphragm separating a cavity of the acoustic device into a front cavity and a back cavity, a first part of the shell corresponding to the front cavity and/or a second part of the shell corresponding to the back cavity is provided with sapphire glass covering the installation hole, and the front cavity is in communication with the outside of the acoustic device through the sound outlet.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Abstract: A coating for protecting a Zirconium alloy based layer of a nuclear fuel rod cladding is provided. The coating comprises a primary layer. A microstructure of the primary layer is comprised of a number of grains and is randomized. The primary layer is configured with a density of about 94.5% or greater. A cladding for a nuclear fuel rod and a method for producing a cladding for a nuclear fuel rod are also provided.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

Abstract: The present invention relates to processes for preparing a Compound (1): or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.

Abstract: A detection result reading device is provided. The detection result reading device includes a reading device body. The reading device body is provided with a cavity at least capable of accommodating a detection part of a reagent card. A side wall of the cavity is provided with a detection result acquisition device, and the detection result acquisition device is arranged opposite to the detection part of the reagent card. The reading device body is provided with a lifting device for lifting the detection part of the reagent card towards a side of the cavity close to the detection result acquisition device.

Abstract: An auxiliary test paper detection device includes a reagent cap and a test paper cassette. The reagent cap contains a detection reagent, a sealing member is arranged at an opening of the reagent cap. The sealing member can be opened or removed under action of external force. Test paper is arranged in the test paper cassette, a sample absorption section of the test paper is exposed, an observation window is formed in the test paper cassette. A result display area of the test paper corresponds to the observation window. A connecting structure for connecting the test paper cassette and the reagent cap is provided, and when the test paper cassette and the reagent cap are connected through the connecting structure, a closed space is formed in an inner cavity of the reagent cap. The sample absorption section of the test paper extends into the inner cavity of the reagent cap.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: Provided are small molecule inhibitors of the KRAS(G12D) mutant oncoprotein having the structural formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: An array substrate including a display area having a plurality of subpixels is provided. The plurality of subpixels includes a plurality of first subpixels in a display-bonding sub-area and a plurality of second subpixels in a regular display sub-area. The array substrate includes a plurality of thin film transistors on a first side of the base substrate and respectively in the plurality of subpixels. A respective one of the plurality of first subpixels includes a bonding pad on a second side of a base substrate; a lead line electrically connecting a respective one of a plurality of thin film transistors to the bonding pad; and a via extending through the base substrate. The lead line is unexposed in the array substrate. The lead line extends from the first side to the second side of the base substrate through the via, to connect to the bonding pad.

Abstract: Provided is a display backplate including an array substrate and a plurality of pairs of connection structures on the array substrate, wherein the array substrate includes a plurality of thin-film transistors and a common electrode signal line, wherein at least one of the plurality of thin-film transistors is connected to one of a pair of connection structures and the common electrode signal line is connected to the other of the pair of connection structures; and an area of a first section of the connection structure is negatively correlated with a distance between the first section and a surface of the array substrate, and the first section is parallel to the surface of the array substrate.